The trajectory of companies tied to flagship drugs like Viagra presents a challenging investment scenario . While the initial boom of copyright, fueled by Viagra's remarkable popularity, generated substantial returns, the loss of exclusivity in key territories has introduced considerable uncertainty . Investors are now facing the effect of generic